Novo Nordisk reports DKK 7.08 billion buyback: Novo Nordisk stock sits 37.02 percent under high

Published on 10/20/2026 at 09:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi cut its target from DKK 310 to DKK 296 on October 9, 2026. Novo Nordisk stock costs EUR 34.55 on October 20, 2026, 0.58 percent above Xetra close.

Capital allocation and timing

Novo Nordisk had accumulated DKK 7.08 billion in repurchases by October 19, 2026.
Citi cut its target from DKK 310 to DKK 296 on October 9, 2026.
Novo Nordisk stock trades at EUR 34.55 at 9:43 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.58 percent above the Xetra close of October 19, 2026.
Novo Nordisk is scheduled to report third-quarter results on November 4, 2026.

Trading Floor Kopenhagen mit Pharma-Index-Charts auf großen Anzeigetafeln — Novo Nordisk A/S (DK0062498333): Börsen-Editorialfoto mit nordischen Pharma-Index-Charts und Händlern auf Kopenhagener Trading-Floor, Illustration mit AI erstellt.

Novo Nordisk reported DKK 7.08 billion in accumulated share repurchases on October 19, 2026, as the drugmaker continued a program of up to DKK 15 billion. The stock was at EUR 34.55 at Lang & Schwarz on October 20, 2026, 0.58 percent above the Xetra close of October 19, 2026.

Buyback reaches DKK 7.08 billion

According to GlobeNewswire on October 19, 2026, Novo Nordisk had repurchased 24.315 million B shares under the program for DKK 7.075 billion. The company said total treasury shares reached 53.115 million, equal to 1.2 percent of share capital.

The wider 12-month program allows repurchases of up to DKK 15 billion from February 4, 2026. By October 16, 2026, total repurchases since the program began stood at 39.074 million B shares for DKK 10.875 billion, giving investors a concrete measure of capital returned through the buyback.

What does the target cut mean for margins?

Yahoo Finance reported on October 9, 2026, that Citi cut its target from DKK 310 to DKK 296 and kept a Neutral rating. Citi reduced its projected 2027 to 2030 earnings-per-share growth from 12 percent to 9 percent, citing limited margin expansion through 2030.

The same report said Citi lifted its 2026 and 2027 adjusted operating profit forecasts by 2 percent to 3 percent and raised its peak sales forecast for the Wegovy pill from USD 10 billion to USD 13 billion. The contrast is central: near-term oral treatment growth is improving, while research and development spending limits the longer-term margin case.

Three dates shape the stock

The recent chronology runs from Citi's DKK 310 to DKK 296 target cut on October 9, 2026, to BMO Capital's reduction from USD 47 to USD 40 on October 12, 2026, reported by Markets Insider, and the DKK 7.075 billion repurchase total on October 19, 2026.

The next date is November 4

Novo Nordisk is scheduled to publish third-quarter results on November 4, 2026, according to Yahoo Finance. Citi forecast third-quarter sales of DKK 73.5 billion, down 4 percent at constant exchange rates from the corresponding period, while Wegovy pill sales were forecast at DKK 5.3 billion, 16 percent above consensus.

Valuation remains below the yearly high

Novo Nordisk's EUR 34.55 reference price is 37.02 percent below the EUR 54.87 52-week high reported for the Xetra listing on October 16, 2026. The market capitalization was EUR 152.5 billion as of October 20, 2026, while the current quote remained only 0.20 euros above the October 19 Xetra close.

Novo Nordisk was trading at EUR 34.55 at Lang & Schwarz on October 20, 2026 at 9:43 a.m. CEST, up 0.58 percent versus the Xetra close of October 19, 2026 at EUR 34.35. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.